134 related articles for article (PubMed ID: 31620878)
21. Olaratumab for the treatment of soft-tissue sarcoma.
Pender A; Jones RL
Future Oncol; 2017 Oct; 13(24):2151-2157. PubMed ID: 28745071
[TBL] [Abstract][Full Text] [Related]
22. Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma.
Pender A; Jones RL
Clin Pharmacol; 2017; 9():159-164. PubMed ID: 29270033
[TBL] [Abstract][Full Text] [Related]
23. Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland.
Gennatas S; Chamberlain F; Carter T; Slater S; Cojocaru E; Lambourn B; Stansfeld A; Todd R; Verrill M; Ali N; Jones RL; Simmonds P; Keay N; McCarty H; Strauss S; Karavasilis V; Dileo P; Benson C
Clin Sarcoma Res; 2020; 10():9. PubMed ID: 32391141
[TBL] [Abstract][Full Text] [Related]
24. Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma.
Schöffski P; Bahleda R; Wagner AJ; Burgess MA; Junker N; Chisamore M; Peterson P; Szpurka AM; Ceccarelli M; Tap WD
Clin Cancer Res; 2023 Sep; 29(17):3320-3328. PubMed ID: 37382656
[TBL] [Abstract][Full Text] [Related]
25. Olaratumab Approved for Soft-Tissue Sarcoma.
Cancer Discov; 2016 Dec; 6(12):1297. PubMed ID: 27827816
[TBL] [Abstract][Full Text] [Related]
26. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Lett; 2019 Jun; 451():122-127. PubMed ID: 30867142
[TBL] [Abstract][Full Text] [Related]
27. Olaratumab for soft tissue sarcoma.
Teyssonneau D; Italiano A
Expert Opin Biol Ther; 2017 Aug; 17(8):1019-1025. PubMed ID: 28691538
[TBL] [Abstract][Full Text] [Related]
28. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
[No Abstract] [Full Text] [Related]
29. Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Jones-Hughes T; Dunham J; Warren FC; Robinson S; Stephens P; Hoyle M
Pharmacoeconomics; 2018 Jan; 36(1):39-49. PubMed ID: 28914440
[TBL] [Abstract][Full Text] [Related]
30. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
Antoniou G; Lee ATJ; Huang PH; Jones RL
Eur J Cancer; 2018 Mar; 92():33-39. PubMed ID: 29413687
[TBL] [Abstract][Full Text] [Related]
31. Olaratumab: First Global Approval.
Shirley M
Drugs; 2017 Jan; 77(1):107-112. PubMed ID: 27995580
[TBL] [Abstract][Full Text] [Related]
32. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Hakenberg OW; Perez-Gracia JL; Castellano D; Demkow T; Ali T; Caffo O; Heidenreich A; Schultze-Seemann W; Sautois B; Pavlik I; Qin A; Novosiadly RD; Shahir A; Ilaria R; Nippgen J
Eur J Cancer; 2019 Jan; 107():186-195. PubMed ID: 30573277
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma.
Vornicova O; Haim N; Bar-Sela G
Cancer Chemother Pharmacol; 2019 Oct; 84(4):919-923. PubMed ID: 31410509
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
Gerber DE; Swanson P; Lopez-Chavez A; Wong L; Dowlati A; Pennell NA; Cronier DM; Qin A; Ilaria R; Cosaert J; Shahir A; Baggstrom MQ
Lung Cancer; 2017 Sep; 111():108-115. PubMed ID: 28838379
[TBL] [Abstract][Full Text] [Related]
35. Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma.
Moore DC; Lavery LA
J Adv Pract Oncol; 2018 Mar; 9(2):235-240. PubMed ID: 30588358
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
Wagner AJ; Kindler H; Gelderblom H; Schöffski P; Bauer S; Hohenberger P; Kopp HG; Lopez-Martin JA; Peeters M; Reichardt P; Qin A; Nippgen J; Ilaria RL; Rutkowski P
Ann Oncol; 2017 Mar; 28(3):541-546. PubMed ID: 28426120
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages.
Del Río-Valencia JC; Asensi-Díez R; Villalobos-Torres L; Clopés-Estela A; Fraga-Fuentes MªD
Farm Hosp; 2018 Sep; 42(5):204-211. PubMed ID: 30173639
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
